menu search

In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting

New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; up...

November 2, 2023, 1:17 pm

Alpha tau announces robust long-term safety and efficacy data from multiple clinical trials of alpha dart

– 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. – Two-year local rec...

August 17, 2023, 9:00 pm

Kymera therapeutics’ stat3 degrader kt-333 and irakimid degrader kt-413 demonstrate desired target knockdown and safety with continued dose escalation in ongoing phase i clinical trials

Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associ...

June 14, 2023, 6:30 am

Kymera therapeutics announces updated clinical data from the phase 1 trials of stat3 degrader kt-333 and irakimid degrader kt-413

Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target...

June 9, 2023, 10:00 pm

Magenta (mgta) down on pipeline update for leukemia drug

Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limitin...

December 21, 2022, 9:02 am

Bellicum announces presentation by unc at ash 2022 on potential abrogation of ic9 car t-cell toxicities with rimiducid

HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunot...

December 11, 2022, 3:00 pm

Olema oncology announces op-1250 demonstrates attractive combinability with cdk 4/6 inhibitor palbociclib in phase 1b dose escalation study

OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- breast cancer, with no dose-limiting ...

December 7, 2022, 8:37 pm

Poseida therapeutics to present early data from phase 1 trials of p-muc1c-allo1 and p-bcma-allo1 at esmo immuno-oncology 2022 annual congress

P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine r...

December 6, 2022, 6:00 am

Karyopharm to present new selinexor data at the 2022 american society of clinical oncology annual meeting

– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Fav...

May 26, 2022, 5:08 pm

Cabaletta bio's updated interim dsg3-caart data fails to cheer investors

Cabaletta Bio Inc (NASDAQ: CABA) presented updated data from the DesCAARTes trial, evaluating DSG3-CAART in adults with mucosal-dominant pemphigus ...

May 18, 2022, 1:04 pm


Search within

Pages Search Results: